Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.12475
Abstract: Paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) is a directâacting antiviral (DAA) approved for the treatment of chronic hepatitis C virus. We report on a probable interaction between PrOD with ribavirin and warfarin. read more here.
Keywords: paritaprevir ritonavir; report; ritonavir ombitasvir; ombitasvir dasabuvir ... See more keywords
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.12917
Abstract: Paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin for 12 weeks are approved for treatment of chronic HCV genotype 1 infection. This study assessed the efficacy of shortened duration paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin… read more here.
Keywords: ritonavir ombitasvir; ombitasvir dasabuvir; infection; paritaprevir ritonavir ... See more keywords